The neuropathology of schizophrenia is substantial in scope and complexity. In patients, structural abnormalities in about 20 brain regions span wide swaths of cortical and subcortical tissue, reflecting processes presumably well advanced at birth. Roughly half as many regions are abnormal in unaffected relatives (cf. Swerdlow, 2011). Within any region, laminar synaptic and cellular arrangements may be perturbed, replacing ‘intended’ spatial and chemical connections with dysfunctional alternatives. The likelihood that medications will functionally untangle these chaotic and dispersed connections in schizophrenia seems increasingly far-fetched.
Cognitive therapies, broadly including cognitive-behavioral and neurorehabilitative therapies and cognitive training, may reduce symptoms and restore function in schizophrenia (McGurk et al, 2007; and Wykes et al, 2008) by engaging healthy neural systems to learn adaptive cognitive and behavioral strategies. The biology underlying learning-based neuroplasticity has been elaborated at levels extending from molecules to systems, and studies are now identifying neural changes accompanying clinical benefits of these specialized ‘learning therapies.’ Conceivably, these neural changes and their corresponding therapeutic impact might be augmented via medications.
Although controlling psychosis benefits ongoing cognitive interventions, drugs with pro-cognitive effects (rather than antipsychotics per se) might more specifically, and perhaps synergistically, enhance the clinical benefits of CTs. Drugs that enhance specific components of neurocognition, eg, working memory (WM), might be predicted to yield clinical benefits in schizophrenia only if paired with interventions that access those components, ie, utilize/place demands on enhanced WM. Similar reasoning underlies the use of anabolic steroids to promote exercise-increased muscle mass, or perhaps more importantly, the use of pro-extinction drugs to enhance therapeutic benefits of cognitive therapies for anxiety disorders (Ressler et al, 2004). Conversely, specific pro-cognitive drugs might be effective in augmenting the clinical benefits of cognitive therapies in schizophrenia even if (as existing data may suggest) they are ineffective when administered without the demands of cognitive therapies.
Initial attempts to develop pharmacologically-augmented cognitive therapies (PACTs) are in progress, using drugs designed to overcome neuropathological changes in schizophrenia (eg, d-cycloserine (Gottlieb et al, 2011)); I have suggested that an alternative strategy might be to utilize medications that enhance spared neural functions in these patients (Swerdlow, 2011). Evidence for the requisite ‘spared’ healthy neural circuitry in any given patient, and hence a target for PACTs, might be provided by specific neurophysiological changes in response to a single drug challenge. The use of a ‘test dose’ to predict clinical benefit has been successful with interventions ranging from hormones to anti-Parkinsonian therapies to bronchodilators. The goal of enhancing ‘spared’ function departs from the prevailing failed strategy of trying to use drugs to ‘undo’ a lifetime of schizophrenia-related neuropathology.
Based on the genetic and neurobiological heterogeneity of schizophrenia, biomarkers might identify subgroups of patients most sensitive to specific PACTs; in some cases, these biomarkers might include neurophysiological measures that identify spared neural circuits in these patients (Javitt et al, 2008). Importantly, the use of PACTs shifts our scientific focus from characterizing the widespread (and I submit, uncorrectable) neuropathology and its molecular antecedents in schizophrenia, to identifying areas of neurobiological resilience and function. In this strategy, our patients’ spared neural resources become the next generation of therapeutic targets for drug development.
References
Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC (2011). D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schiz Research 131: 69–74.
Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7: 68–83.
McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007). A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164: 1791–1802.
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E et al (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136–1144.
Swerdlow NR (2011). Are we studying and treating schizophrenia correctly? Schiz Res 130: 1–10.
Wykes T, Steel C, Everitt B, Tarrier N (2008). Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 34: 523–537.
Acknowledgements
Supported by MH93453, MH59803, MH42228, MH65571, and DA27483. The author has benefited greatly from discussions with his valued colleagues, including Drs Nancy Downs, Gregory Light, David Braff, and Elizabeth Twamley.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received consulting fees from Neurocrine Pharmaceutical.
Rights and permissions
About this article
Cite this article
Swerdlow, N. Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia. Neuropsychopharmacol 37, 310–311 (2012). https://doi.org/10.1038/npp.2011.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2011.195
This article is cited by
-
Memantine effects on auditory discrimination and training in schizophrenia patients
Neuropsychopharmacology (2020)
-
Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients
Neuropsychopharmacology (2018)
-
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis
Neuropsychopharmacology (2016)